Strategic partnerships EpiCypher has recent and high-profile collaboration activity with Abcam, New England Biolabs, and Fred Hutch licensing partners, indicating openness to co-development and distribution models that sales teams can leverage to propose joint solutions and expanded channel opportunities.

Expansion catalysts Launches of Fiber-seq and CUTANA Fiber-seq, plus multiomic capabilities, signal a rapid expansion of product breadth in single-molecule chromatin mapping that can cross-sell to existing customers and attract new labs seeking advanced epigenomics tools.

Strategic fit Strong focus on epigenetics and chromatin biology aligns with core R&D pipelines in life sciences, enabling cross-sell into sequencing core facilities, biotech startups, and academic centers investing in epigenomics research.

Technology leverage Partnership with PacBio for Fiber-seq enzymes and a robust tech stack supporting analytics and support (Tech Support Center) create opportunities to position bundled workflows, CRO collaborations, and product integrations for end-to-end epigenomic solutions.

Financial and scale signals Mid-market revenue range and recent funding indicate growth potential and willingness of customers to invest in innovative tools; sales motion can target mid-sized biotech and contract research organizations seeking cutting-edge epigenomics capabilities.